Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone for Grade 2/3 Radiation-induced Lung Injury
NCT03902509Phase 2Completed
- Sponsor
- Gyre Pharmaceuticals
- Start
- May 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirfenidone in radiation-induced lung injury (RILI), sponsored by Gyre Pharmaceuticals. Started May 2019; status: completed.
02
Drugs
pirfenidone
03
Conditions
radiation-induced lung injury (RILI)
Beyond the preview
Go deeper on NCT03902509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03902509.